plus gemcitabine

Related by string. * PLus . PLUS . PLU . Plus . Plu : Action Alerts PLUS . #.# plus GST . Dolby Digital Plus . Wii Fit Plus . Canal Plus . Kate Plus . Plus Size . plus GST payable . Proved plus / Gemcitabine : Gemzar gemcitabine . gemcitabine Gemzar . cisplatin gemcitabine . gemcitabine cisplatin . gemcitabine Gemzar ® . gemcitabine Gemzar R . Gemcitabine HCI . gemcitabine carboplatin * *

Related by context. All words. (Click for frequent words.) 77 plus dexamethasone 74 FOLFOX4 74 5-FU/LV 73 carboplatin paclitaxel 72 ACTEMRA TM 72 unresectable stage 72 FOLFOX 71 ribavirin RBV 71 pegylated liposomal doxorubicin 71 infusional 5-FU/LV 71 alfa 2a 71 FOLFIRI 71 5 FU leucovorin 71 gemcitabine chemotherapy 71 achieved ACR# 70 paclitaxel carboplatin 70 plus prednisone 70 metastatic renal cell carcinoma 70 FOLFOX6 70 FOLFOX4 alone 70 interferon alfa 2a 70 stage IIIb IV 70 gemcitabine carboplatin 70 FOLFIRI alone 70 trastuzumab Herceptin R 70 VELCADE melphalan 70 dacarbazine 70 placebo dexamethasone 70 8mg/kg 70 Xeloda ® 70 estramustine 70 comparator arm 69 lopinavir r arm 69 relapsed refractory multiple myeloma 69 Fludara 69 Peg IFN 69 FluCAM 69 gemcitabine cisplatin 69 Folfox 69 docetaxel chemotherapy 69 evaluating tivozanib 69 Taxotere ® 69 5 fluorouracil leucovorin 69 chlorambucil 69 vinorelbine 69 cisplatin vinorelbine 69 dacarbazine DTIC 69 plus prednisone prednisolone 69 sorafenib Nexavar ® 68 melphalan prednisone 68 gemcitabine 68 pegylated interferon alfa 2b 68 octreotide LAR 68 cyclophosphamide chemotherapy 68 mitoxantrone plus 68 fluoropyrimidine 68 FOLFOX6 chemotherapy regimen 68 Pegasys ® 68 mcg kg REBETOL 68 docetaxel Taxotere R 68 recurrent NSCLC 68 Tarceva TM 68 ELOXATIN 68 Flu Cy 68 metastatic CRC 68 irinotecan doxorubicin oxaliplatin paclitaxel 68 Free Survival PFS 68 FUSILEV enhances 68 leukemia AML 68 receiving INTRON 68 pegylated interferon alfa 2a 67 interferon alfa 67 cisplatin gemcitabine 67 TAXOTERE R 67 peripheral sensory neuropathy 67 mg QD 67 low dose cytarabine 67 Amrubicin 67 TO AVOID PREGNANCY WHILE 67 q#h 67 pegylated interferon peg IFN 67 dasatinib Sprycel ® 67 oxycodone CR 67 fluorouracil 67 plus methotrexate 67 metastatic GIST 67 alpha interferons 67 Doxil ® 67 severe neutropenia 67 #mg BID [001] 67 highly emetogenic 67 unresectable HCC 67 pegylated interferon alpha 67 temsirolimus 67 BR.# 67 mg BID 67 docetaxel Taxotere ® 67 anthracycline taxane 67 NEUPOGEN 67 nab paclitaxel 67 CIMZIA TM 67 Neulasta R 67 sorafenib Nexavar 67 Median PFS 67 lopinavir r 67 Gemzar ® 67 relapsed MM 67 pertuzumab 67 paclitaxel Taxol ® 67 cabazitaxel 67 decitabine 67 SPRYCEL ® 67 sunitinib Sutent 67 R sorafenib tablets 67 metastatic castration resistant 67 Torisel 66 forodesine 66 ZACTIMA 66 cyclophosphamide methotrexate 66 patients receiving ERBITUX 66 stage IIIB 66 recurrent glioblastoma multiforme 66 monotherapy 66 erlotinib Tarceva ® 66 metastatic colorectal 66 CR nPR 66 docetaxel Taxotere 66 febrile neutropenia 66 KRAS mutations occur 66 CIMZIA ™ 66 sunitinib malate 66 sunitinib Sutent ® 66 mRCC 66 Camptosar ® 66 BARACLUDE ® 66 mapatumumab 66 Peginterferon alfa 2b 66 Taxotere R 66 recurrent metastatic 66 EGFR mutation positive 66 infliximab monotherapy 66 Fludara ® 66 irinotecan chemotherapy 66 oral ridaforolimus 66 Pemetrexed 66 PEGylated Fab fragment 66 Hycamtin ® 66 novel VDA molecule 66 bevacizumab Avastin R 66 Irinotecan 66 lenalidomide Revlimid R 66 Cimzia TM 66 relapsed multiple myeloma 66 CYT# potent vascular disrupting 66 Epothilone D 66 Elitek 66 cetuximab Erbitux ® 66 capecitabine Xeloda 66 induced macular edema 66 discontinuations due 66 adalimumab Humira 66 bendamustine 66 refractory NSCLC 66 Pegasys plus Copegus 66 CANCIDAS 66 active comparator 66 platinum refractory 66 pain palliation 66 Meets Primary Endpoint 66 Aflibercept 66 telaprevir dosed 66 occlusion PAO 66 tenofovir emtricitabine 66 PegIFN 66 humanized interleukin 6 66 Pegasys peginterferon alfa 2a 66 ® lenalidomide 66 unresectable locally advanced 66 Ixempra 66 daunorubicin 66 COPEGUS 66 cell lymphoma CTCL 66 vandetanib 66 XIENCE V PROMUS Stent 65 Paraplatin ® 65 relapsed myeloma 65 lenalidomide dexamethasone 65 receiving prophylactic anticoagulation 65 gemcitabine Gemzar 65 MAGE A3 ASCI 65 XELOX 65 Hsp# Inhibitor 65 HER2 positive metastatic breast 65 standard chemotherapy regimen 65 CHOP chemotherapy 65 docetaxel 65 TORISEL 65 recurrent glioblastoma 65 refractory chronic lymphocytic 65 advanced unresectable 65 TTF Therapy 65 oblimersen 65 peginterferon alfa 2b 65 glufosfamide 65 cetuximab Erbitux R 65 peginterferon alfa 2a 65 BRIM2 65 bosutinib 65 FEMALES SHOULD BE ADVISED 65 dasatinib Sprycel 65 AAG geldanamycin analog 65 pemetrexed 65 plus 5-FU/LV 65 mcg albinterferon alfa 2b 65 treatment naïve genotype 65 KRAS wild 65 Copegus ribavirin 65 docetaxel prednisone 65 zalutumumab 65 mcg QD 65 oral Hycamtin 65 squamous histology 65 Platinol ® cisplatin 65 mCRC patients 65 sorafenib tablets 65 mitoxantrone 65 DOXIL 65 chemoradiation 65 headache nasopharyngitis 65 PEG Interferon alfa 65 oral chemotherapeutic agent 65 Diffuse Large B 65 PEG Intron 65 #mg BID [003] 65 rosuvastatin #mg 65 chemotherapy cisplatin 65 chemoradiotherapy 65 oral allopurinol 65 metastatic malignant 65 Alocrest 65 imatinib Gleevec ® 65 adriamycin 65 Jevtana 65 Vidaza ® 65 Xanafide 65 brand ciclesonide HFA 65 BRAF inhibitor 65 beclomethasone dipropionate 65 CIMZIA TM certolizumab pegol 65 ZYBRESTAT 65 mitomycin 65 non metastatic osteosarcoma 65 nilotinib Tasigna ® 65 virus HCV protease inhibitor 65 PEGINTRON TM 65 HBeAg positive patients 65 oxaliplatin Eloxatin 65 Peginterferon 65 Lenalidomide 65 Patients Treated With 65 q8h 65 TAXOTERE ® 65 metastatic castrate resistant 65 aflibercept 65 capecitabine 65 Navelbine 65 cutaneous T cell 65 FOLFOX chemotherapy 65 PROSTVAC VF 65 gemcitabine Gemzar ® 65 TYKERB 65 MGd 65 receptor tyrosine kinase inhibitor 65 cutaneous T 65 ritonavir boosted 65 unresectable 65 beta 1a 65 advanced hepatocellular carcinoma 65 clodronate 64 systemic ALCL 64 Imprime PGG 64 μg dose 64 heavily pretreated 64 axitinib 64 5 fluorouracil 64 hormone refractory metastatic prostate 64 AVASTIN 64 Aptivus ® 64 sirolimus eluting stent 64 R# #mg BID 64 PREZISTA r 64 achieved CCyR 64 interferon gamma 1b 64 mycophenolate mofetil 64 4mg/kg 64 Chronic Hepatitis C 64 ribavirin therapy 64 pan histone deacetylase 64 lintuzumab SGN 64 locoregional 64 plus GP IIb 64 Achieves Primary Endpoint 64 PREZISTA rtv 64 epirubicin cyclophosphamide 64 LymphoStat B belimumab 64 pan HDAC inhibitor 64 cetuximab Erbitux 64 locoregional disease 64 amrubicin 64 dextromethorphan quinidine 64 oral clodronate 64 #mg QD [002] 64 Gemcitabine 64 bone marrow reticulin deposition 64 #mg/m# [001] 64 goserelin 64 unresectable Stage III 64 non squamous NSCLC 64 hepatocellular cancer 64 Platinol 64 MCyR 64 Bevacizumab 64 folinic acid FA 64 eribulin mesylate 64 essential thrombocythemia ET 64 metastatic colorectal carcinoma 64 INCB# [001] 64 eribulin 64 plus OBT 64 metastatic pancreatic 64 tipranavir r 64 advanced NSCLC 64 peg IFN 64 biologic DMARD 64 anthracyclines taxanes 64 intravesical infusion therapy 64 Cutaneous T 64 thalidomide Thalomid 64 Hazard Ratio 64 modified glutathione analog 64 Zorbtive TM 64 IIIa inhibitor 64 metastatic hormone refractory 64 MabCampath 64 cilengitide 64 vidofludimus 64 bevacizumab Avastin ® 64 Alkeran 64 demonstrated antitumor activity 64 malignancy HCM 64 TELCYTA 64 tapentadol ER 64 Myelodysplastic Syndrome MDS 64 TMC# r 64 ug dose 64 vincristine doxorubicin 64 receiving PEGINTRON 64 retinal vein occlusion induced 64 Peginterferon Alfa 2a 64 ZACTIMA TM ZD# 64 REVLIMID ® 64 Seliciclib 64 APTIVUS r 64 tumor lysis syndrome 64 fluvastatin 64 gefitinib Iressa 64 alpha 2b 64 severe oral mucositis 64 doxorubicin docetaxel 64 R Saizen R 64 Trial Evaluating 64 Temsirolimus 64 mTOR inhibitor 64 interferon beta 1a infertility 64 metastatic renal cell 64 refractory metastatic colorectal cancer 64 FOLPI 64 bortezomib Velcade R 64 nadroparin 64 paclitaxel Taxol 64 zonisamide SR 64 HBeAg negative patients 64 AVONEX ® 64 Telik logo TELINTRA 64 vinorelbine tartrate 64 lispro 64 Improved Progression 63 azacitidine 63 neurologic progression 63 vapreotide acetate 63 ritonavir boosted atazanavir 63 idarubicin 63 catheter occlusion 63 INSPIRE Trial Phase III 63 certolizumab 63 custirsen 63 abacavir lamivudine 63 dalteparin 63 KRAS mutant tumors 63 opioid induced constipation OIC 63 complete cytogenetic response 63 paclitaxel chemotherapy 63 huC# DM4 63 mg q#h 63 orally administered inhibitor 63 assessing T DM1 63 TELINTRA 63 doxorubicin cyclophosphamide 63 LEXIVA r 63 concurrent chemoradiation 63 Platinol ® 63 mg qd 63 Panzem R NCD 63 liposomal formulation 63 mg m² 63 plus COPEGUS 63 relapsing multiple sclerosis 63 CTAP# Capsules 63 weekly subcutaneous injections 63 nonmetastatic 63 autoantibody positive 63 TAXUS Express Stent 63 COMBIVIR 63 Pharmacokinetics PK 63 HuMax EGFr 63 Zometa hazard 63 chemoradiation therapy 63 antibody MAb 63 IFN alfa 63 xanthine oxidase inhibitor 63 EGFR TKI 63 recurrent genital herpes 63 virologic failure 63 IMiDs ® compound 63 saline placebo 63 Thal Dex 63 cyclophosphamide doxorubicin vincristine 63 dose dexamethasone 63 severe hypersensitivity reactions 63 Median progression 63 vinca alkaloid 63 sapacitabine 63 refractory AML 63 registrational trial 63 ® bortezomib 63 salmeterol fluticasone 63 Fludarabine 63 monoclonal antibody IgG1 Mab 63 FOR FURTHER INFORMATION ABOUT 63 Albuferon TM 63 CCyR 63 Hormone Refractory Prostate Cancer 63 baminercept 63 Engerix B 63 ceftazidime 63 PREZISTA ritonavir 63 paclitaxel cisplatin 63 Capecitabine 63 teriflunomide 63 fallopian tube cancers 63 RGT arm 63 Pegylated Interferon 63 CRu 63 peginterferon alfa 2a Pegasys 63 FluCAM arm 63 Halaven 63 glycoprotein IIb IIIa inhibitor 63 oral rivaroxaban 63 PEGylated interferon beta 1a 63 myelodysplastic myeloproliferative diseases 63 Study Evaluating 63 IV NSCLC 63 peginterferon alfa 63 somatostatin analog 63 HBeAg negative 63 developing Bicifadine serotonin 63 hypophosphatemia 63 potent CYP#A# inhibitors 63 novel emulsion formulation 63 median PFS 63 FOLFIRI chemotherapy 63 Glufosfamide 63 dasatinib 63 idraparinux 63 incidence ≥ 63 Epratuzumab 63 cytarabine daunorubicin 63 refractory multiple myeloma 63 ELACYT 63 thromboembolic events 63 TNF Tumor Necrosis Factor 63 Oral Fingolimod 63 #mg/day [001] 63 RAPTIVA 63 5FU 63 ara C 63 PEG interferon 63 indolent follicular non 63 evaluable 63 aspirin heparin 63 BARACLUDE R 63 Navelbine ® 63 phase IIb study 63 neutropenia dehydration dyspnea 63 multiple myeloma MM 63 Xelox 63 5 Fluorouracil 63 patients coinfected 63 R rilonacept Injection 63 pamidronate 63 mcg BID 63 relapsed SCLC 63 dacarbazine chemotherapy 63 Pivotal Phase III 63 lymphoma CTCL 63 pomalidomide 63 Pegylated Liposomal Doxorubicin 63 OPAXIO 63 ARCALYST ® 63 IMiDs ® 63 myocardial infarction ventricular fibrillation 63 systemic anaplastic large 63 DexaSite 63 receiving VELCADE 63 chemotherapy FOLFOX 63 desvenlafaxine succinate 63 ® natalizumab 63 plus dacarbazine 63 interferon beta therapy 63 regorafenib 63 Ophena TM 63 ARCOXIA 63 amoxicillin clavulanate 63 elotuzumab 63 PEGylated anti 63 neoadjuvant 63 paclitaxel poliglumex 62 stage IIIB IV 62 RLAI 62 topotecan 62 metastatic RCC 62 glioblastoma multiforme GBM 62 dependent kinase inhibitor 62 leukopenia 62 patients evaluable 62 Relapsed Refractory 62 Taxotere 62 posaconazole 62 EGFR expressing mCRC 62 EURIDIS 62 oral nucleoside analogue 62 temsirolimus Torisel ® 62 YONDELIS 62 huN# DM1 62 recurrent GBM 62 radiochemotherapy 62 generation purine nucleoside 62 ACTEMRA 62 Initiate Phase 62 neratinib 62 EFAPROXYN 62 prostate cancer HRPC 62 antiretroviral naïve 62 adjunctive placebo 62 TNF antagonists 62 fallopian tube carcinoma 62 gastrointestinal stromal tumor GIST 62 prednisone prednisolone plus 62 oropharyngeal candidiasis OPC 62 galiximab 62 equi analgesic doses 62 Phase 2b Clinical Trial 62 abiraterone acetate 62 locoregional recurrence 62 SinuNase TM 62 Randomized Phase 62 Taxotere docetaxel 62 carboplatin 62 doublet chemotherapy 62 interferon alfa 2b 62 Allovectin 7 62 Pooled Analysis 62 arthritis PsA 62 receiving highly emetogenic 62 ancrod 62 Relapsed Refractory Multiple Myeloma 62 PREZISTA r arm 62 NEVO ™ 62 R lenalidomide 62 Vfend 62 tumors GIST 62 investigational antiplatelet agent 62 metaglidasen 62 INTEGRILIN R 62 naïve HCV 62 refractory metastatic 62 metformin sulfonylurea 62 nitazoxanide 62 trabectedin 62 methotrexate monotherapy 62 panitumumab 62 cisplatin carboplatin 62 exemestane Aromasin 62 ribavirin Copegus ® 62 carboplatin chemotherapy 62 cancer mCRC 62 fatigue asthenia 62 biochemical relapse 62 Pivotal Phase 62 azilsartan medoxomil 62 PegIntron 62 Nexavar sorafenib 62 remission induction 62 CRp 62 boosted protease inhibitor 62 oral FTY# 62 Azixa 62 iniparib 62 splenectomized 62 imatinib resistant 62 canakinumab 62 hour bronchodilation 62 Pegintron 62 mutated KRAS 62 erlotinib Tarceva R 62 non splenectomized 62 Vandetanib 62 Ovitrelle R Serostim 62 interferon ribavirin 62 TRANSFORMS 62 relapsed CLL 62 mg ustekinumab 62 pharmacologically active isomer 62 Campath alemtuzumab 62 mg TID 62 PI3K/Akt pathway inhibitor 62 LPV r 62 AZT zidovudine Retrovir 62 oral diclofenac 62 chemotherapy gemcitabine 62 visilizumab 62 aflibercept VEGF Trap 62 cisplatin chemotherapy 62 SUPPRELIN R LA 62 uric acid lowering 62 free survival PFS 62 #mg q8h 62 Panzem NCD 62 Interferon alfa 62 acetonide FA 62 stage IIIb 62 2 methoxyestradiol 62 Vicinium TM 62 PegIFN RBV 62 Mitoxantrone 62 RhuDex ® 62 oxymorphone ER 62 PNP inhibitor 62 PD LID 62 Vidaza azacitidine 62 phase IIb clinical 62 FTY# fingolimod 62 HBeAg seroconversion 62 follicular lymphoma FL 62 sorafenib Nexavar R 62 Evoltra ® 62 Pegasys R 62 sargramostim 62 pyrexia mucositis sepsis febrile 62 recurrent metastatic ovarian cancer 62 Mg Usa 62 PEGASYS ® 62 Metastatic Colorectal Cancer 62 AzaSite Plus 62 novel histone deacetylase 62 Brentuximab Vedotin SGN 62 acute peripheral arterial 62 nasopharyngitis 62 placebo PBO 62 Nexavar ® 62 Bosutinib 62 VEGFR2 inhibitor 62 mg/m2 dose 62 Acetate Rectal Suppositories 62 VaD 62 DOXIL ® 62 FOLFOX regimen 62 evaluating picoplatin 62 Neulasta ® 62 Omacetaxine 62 bosentan 62 PEG IFN 62 Taxotere chemotherapy 62 YERVOY 62 PEG INTRON 62 imipenem 62 ThermoDox R 62 protease inhibitor PI 62 #mg dosing group 62 double blinded placebo 62 BCG refractory carcinoma 62 treatment naive genotype 62 nadolol 62 Phase IIb Trial 62 AGILECT R 62 darunavir r 62 Dasatinib 62 RoACTEMRA 62 COPEGUS ribavirin 62 Infusion reactions 62 Allovectin 7 ® 62 Darusentan 62 alkylating agent 62 panitumumab Vectibix 62 MT# MEDI 62 Amgen Neulasta R 62 Peginterferon alfa 2a 62 VFEND 62 Previously Untreated 62 INC# 62 plus ribavirin 62 FASLODEX 62 Voreloxin 62 GOUT 62 Toxicities 62 adjunctive ABILIFY 62 thetreatment 62 aplastic anemia AA 62 mg/m2 IV 62 brivaracetam 62 Vaprisol 62 resistant hormone refractory 62 bleeding pallor 62 Safinamide 61 tumor progression TTP 61 ADP receptor antagonist 61 peg interferon 61 ZOLINZA 61 Orally administered 61 oxycodone IR 61 recurrent squamous cell carcinoma 61 MYDICAR ® 61 ABVD 61 Bezielle 61 lymphoid malignancies 61 Lenocta TM 61 Ceplene/IL-2 61 evaluable subjects 61 RG# ITMN 61 sunitinib 61 liposomal doxorubicin 61 XL# anticancer compounds 61 histone deacetylase HDAC inhibitor 61 Monotherapy 61 Clolar ® 61 non resectable 61 refractory CTCL 61 Xeloda capecitabine 61 progression TTP 61 Infusion Reactions Severe 61 temsirolimus Torisel 61 IRX 2 61 p = NS 61 Novantrone 61 Fulvestrant 61 PRT# 61 pegylated interferon 61 Antitumor Activity 61 Adjuvant Treatment 61 chemoembolization 61 biliary tract cancer 61 investigational immunotherapy 61 diarrhea vomiting nausea 61 unfractionated heparin UFH 61 Cell Lymphoma 61 #.#mg/dL 61 paclitaxel 61 CTA# Injection 61 amphotericin B 61 Newly Diagnosed Multiple Myeloma 61 metastatic HER2 negative 61 ORENCIA ® 61 binary restenosis 61 mcg kg 61 RhuDex R 61 Adjuvant chemotherapy 61 Genentech Rituxan 61 Multiple Myeloma MM 61 cisplatin 61 TREANDA 61 Budesonide foam crofelemer 61 tumor xenograft models 61 prulifloxacin 61 ABC/3TC 61 partial remissions 61 BUPHENYL R sodium phenylbutyrate 61 receiving golimumab 61 zolmitriptan 61 DU #b 61 XGEVA 61 novel topoisomerase 61 CYPHER Stent 61 Phase #b/#a clinical 61 MEK Inhibitor 61 Entereg R 61 UPLYSO 61 taxane refractory 61 ALN HPN 61 heavily pretreated patients 61 flutamide 61 previously untreated follicular 61 azathioprine 61 PROSTVAC ® 61 achieved PASI 61 PAOD 61 RANK Ligand inhibitor 61 ISTODAX ® 61 PROVENGE ® 61 low dose dexamethasone 61 oral prodrug 61 tolterodine ER 61 ribavirin USP 61 Severe Sepsis 61 invasive candidiasis 61 post herpetic neuralgia PHN 61 evaluating T DM1 61 HGS# 61 PROCTOCORT ® Suppository Hydrocortisone 61 NMIBC 61 EDEMA3 61 nucleoside analog 61 FROVA 61 pancreatic NET 61 TAXUS Element Paclitaxel Eluting 61 neutropaenia 61 lexidronam injection 61 metformin HCl 61 Kepivance 61 Eloxatin R 61 basal cell carcinoma BCC 61 mitoxantrone chemotherapy 61 adjuvant GIST 61 metastatic carcinoma 61 refractory gout 61 androgen independent 61 3TC lamivudine Epivir 61 tirofiban 61 TELINTRA R 61 non nucleoside inhibitor 61 urate lowering 61 Targretin 61 IXEMPRA 61 tamoxifen Nolvadex ® 61 non valvular atrial 61 ATACAND 61 Aloxi injection 61 adjuvant colon cancer 61 EndoTAGTM 1 61 PKC# 61 postoperative chemotherapy 61 pancreatic prostate 61 mGluR5 negative 61 dexamethasone Decadron 61 pegylated interferon alpha 2a 61 drotrecogin alfa activated 61 gastrointestinal perforation 61 ErbB2 positive 61 hematologic toxicity 61 Thalomid ® 61 ixabepilone 61 DCVax ® Brain 61 inhibitor RG# 61 investigational protease inhibitor 61 crizotinib PF # 61 K ras mutations 61 painful diabetic neuropathy 61 Targretin capsules 61 bevacizumab Avastin 61 pegylated liposomal doxorubicin PLD 61 anthracycline containing 61 COPEGUS R 61 piperacillin tazobactam 61 SCCHN 61 receiving VICTRELIS 61 Refractory Hodgkin Lymphoma 61 GW# [003] 61 cytokine refractory 61 de novo kidney transplant 61 somatostatin analogue 61 oral levofloxacin 61 trabedersen 61 SVR# 61 RG# [001] 61 neoadjuvant treatment 61 iniparib BSI 61 alvespimycin 61 imatinib Gleevec 61 Sanofi Aventis Taxotere 61 irinotecan containing 61 hyperphenylalaninemia HPA due 61 aspirin clopidogrel 61 cediranib 61 Gleevec imatinib mesylate 61 Mg Uk 61 Degarelix 61 adalimumab 61 multi kinase inhibitor 61 pancreatic adenocarcinoma 61 Median survival 61 Known hypersensitivity 61 thrombocytopenic 61 letrozole Femara 61 Oral NKTR 61 delivers fluocinolone acetonide FA 61 complement inhibitor eculizumab 61 AGILECT ® 61 chronic myeloid 61 resminostat 61 Quinamed 61 Ozarelix 61 neoadjuvant chemotherapy 61 pooled comparator 61 SCH # 61 Hodgkin lymphoma HL 61 olmesartan 61 PANVAC VF 61 sapacitabine CYC# 61 MYLOTARG 61 hypoxia activated prodrug 61 Dose Escalation 61 EXPAREL TM 61 MKC# MT 61 Velcade bortezomib 61 subependymal giant cell 61 evaluating satraplatin 61 Copegus ® 61 pegfilgrastim 61 Phase 2b clinical 61 alemtuzumab treated 61 dapagliflozin plus 61 MyVax R 61 nicardipine 61 Gleevec resistant 61 diabetic neuropathic pain 61 ARB telmisartan 61 HCV RESPOND 2 61 metastatic androgen independent 61 maximally tolerated dose 61 IMiDs R 61 ARCALYST 61 mertansine 61 telaprevir dosing 61 NOXAFIL 61 Initiates Phase II 61 bortezomib Velcade 61 morphometric vertebral fractures 61 pediatric Crohn disease 61 #mg/m# [002] 61 Dementia Related Psychosis 61 Archexin 61 gp# vaccine 61 anti EGFR antibody 61 Temodar ® 61 LymphoStat B TM 61 trastuzumab DM1 61 zoledronic acid 61 satraplatin Phase 61 rasagiline tablets 61 Genasense ® 61 Fluorouracil 61 Herceptin trastuzumab 61 ongoing Phase 1b 61 anti leukemic 61 Elotuzumab 61 lumiliximab 61 nilotinib 61 prior chemotherapy regimens 61 % CI #.#-#.# [003] 61 chronic angina 61 fludarabine phosphate 61 carcinoma mCRC 61 Philadelphia Chromosome Positive 61 definite stent thrombosis 61 non resectable metastatic 60 Inhalation Solution 60 Pivotal Trial 60 omega interferon 60 cetuximab 60 Doxil 60 Wafer polifeprosan 60 INTEGRILIN ® 60 Afinitor ® 60 XIENCE V demonstrated 60 REVLIMID R 60 lapatinib Tykerb 60 virologic breakthrough 60 salmeterol fluticasone propionate 60 3mg/kg 60 adecatumumab

Back to home page